Berlin-based biotechnology company developing antibody-based cancer therapeutics that target tumor-associated carbohydrate antigens (TACAs)
Berlin-based biotechnology company developing antibody-based cancer therapeutics that target tumor-associated carbohydrate antigens (TACAs). Its proprietary glycan biology and chemical platform generates and validates antibodies for potential treatment modalities including antibody-drug conjugates and T-cell engagers. The company has a pipeline of seven projects across solid tumor indications.